- France
- /
- Aerospace & Defense
- /
- ENXTPA:EXENS
European Stocks With Estimated Discounts Up To 41.3%
Reviewed by Simply Wall St
Amidst concerns over U.S. trade tariffs and uncertainty in monetary policy, the European markets have experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending 1.23% lower recently. Despite these challenges, investors may find opportunities in undervalued stocks that offer potential for growth by trading below their intrinsic value, making them attractive options in today's cautious market environment.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Name | Current Price | Fair Value (Est) | Discount (Est) |
Telefonaktiebolaget LM Ericsson (OM:ERIC B) | SEK83.02 | SEK164.54 | 49.5% |
Wienerberger (WBAG:WIE) | €35.24 | €69.57 | 49.3% |
CTT Systems (OM:CTT) | SEK228.00 | SEK443.67 | 48.6% |
Net Insight (OM:NETI B) | SEK4.92 | SEK9.58 | 48.6% |
Storytel (OM:STORY B) | SEK90.85 | SEK180.37 | 49.6% |
Star7 (BIT:STAR7) | €6.30 | €12.42 | 49.3% |
InTiCa Systems (XTRA:IS7) | €4.22 | €8.25 | 48.9% |
Fodelia Oyj (HLSE:FODELIA) | €7.12 | €13.91 | 48.8% |
MilDef Group (OM:MILDEF) | SEK208.50 | SEK405.57 | 48.6% |
Galderma Group (SWX:GALD) | CHF96.38 | CHF189.25 | 49.1% |
We'll examine a selection from our screener results.
Netcompany Group (CPSE:NETC)
Overview: Netcompany Group A/S delivers essential IT solutions to both private and public sectors across several countries including Denmark, Norway, the UK, and others, with a market cap of DKK13.33 billion.
Operations: The company's revenue is derived from two main segments: Public, contributing DKK4.50 billion, and Private, generating DKK2.04 billion.
Estimated Discount To Fair Value: 41.3%
Netcompany Group is trading at DKK 283.2, significantly below its estimated fair value of DKK 482.28, indicating it may be undervalued based on cash flows. With earnings expected to grow at a robust 23.3% annually over the next three years—outpacing the Danish market's average—the company shows potential despite slower revenue growth forecasts due to challenges in public spending and strategic divestments impacting future revenue levels. Recent AGM decisions include share capital reduction and bylaw amendments.
- Our growth report here indicates Netcompany Group may be poised for an improving outlook.
- Unlock comprehensive insights into our analysis of Netcompany Group stock in this financial health report.
Exosens (ENXTPA:EXENS)
Overview: Exosens develops, manufactures, and sells electro-optical technologies focused on amplification, detection, and imaging across France and international markets with a market cap of €1.73 billion.
Operations: The company's revenue is primarily derived from its amplification segment, contributing €280.20 million, and its detection and imaging segment, generating €117.50 million.
Estimated Discount To Fair Value: 34.9%
Exosens, trading at €34.11, is significantly undervalued with a fair value estimate of €52.39 based on discounted cash flow analysis. Despite recent share price volatility, the company's earnings are projected to grow substantially at 23% annually, surpassing the French market average. Recent investments in U.S. production facilities and strong demand for night vision technology underscore Exosens' strategic positioning in defense markets, enhancing its potential for future revenue growth despite slower overall revenue forecasts compared to earnings growth expectations.
- The analysis detailed in our Exosens growth report hints at robust future financial performance.
- Click here to discover the nuances of Exosens with our detailed financial health report.
Yara International (OB:YAR)
Overview: Yara International ASA is a global provider of crop nutrition and industrial solutions, operating across multiple continents with a market cap of NOK87.40 billion.
Operations: Yara International ASA generates revenue through its segments in Europe ($4.36 billion), Americas ($4.78 billion), Africa & Asia ($2.85 billion), Clean Ammonia ($1.81 billion), Industrial Solutions ($2.42 billion), and Global Plants & Operational Excellence ($2.94 billion).
Estimated Discount To Fair Value: 13%
Yara International, trading at NOK343.1, is undervalued with a fair value estimate of NOK394.33 based on discounted cash flow analysis. Despite high debt levels and a recent net loss of US$290 million for Q4 2024, earnings are forecast to grow significantly at 38.1% annually, outpacing the Norwegian market average. While profit margins have declined, Yara's revenue growth is expected to surpass the local market rate slightly at 3% per year.
- In light of our recent growth report, it seems possible that Yara International's financial performance will exceed current levels.
- Click here and access our complete balance sheet health report to understand the dynamics of Yara International.
Key Takeaways
- Access the full spectrum of 208 Undervalued European Stocks Based On Cash Flows by clicking on this link.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
If you're looking to trade Exosens, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if Exosens might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:EXENS
Exosens
Engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally.
Solid track record with reasonable growth potential.
Market Insights
Community Narratives
